BioMarin to Acquire Alesta Therapeutics for $275M Upfront, Up to $215M in Milestones

summarizeSummary

BioMarin signed a definitive agreement to acquire Alesta Therapeutics for $275M upfront plus up to $215M in milestones, gaining ALE1, a potential first oral therapy for hypophosphatasia.

check_boxKey Events · M&A and Partnerships · BMRN

• Acquisition of Alesta Therapeutics

  BioMarin signed a definitive Share Purchase Agreement to acquire Alesta Therapeutics B.V. for $275M upfront cash, subject to post-closing adjustment, plus up to $215M in development and regulatory milestone payments.

• ALE1: First Oral HPP Therapy

  The deal centers on ALE1, an orally active small molecule for hypophosphatasia (HPP) currently in a Phase 1/2a trial. If approved, it would be the first oral therapy targeting the disease metabolite PPi.

• Spin-Out Structure

  Alesta will spin out all non-ALE1 assets to a new entity (SpinCo) prior to closing. No Alesta employees will transfer to BioMarin, reducing integration risk.

• Closing Expected Q3 2026

  The transaction is expected to close in Q3 2026, subject to customary conditions including completion of the Spin-Out and absence of legal restraints.

auto_awesomeAnalysis · BMRN · Life Sciences

The acquisition of Alesta Therapeutics gives BioMarin ALE1, a Phase 1/2a oral therapy for hypophosphatasia (HPP), and the $275M upfront plus up to $215M in milestones is a substantial but manageable capital deployment for a $12.9B company. The deal adds a clinical-stage asset targeting a rare bone disease with an addressable patient population BioMarin describes as its largest potential market. The spin-out structure means BioMarin acquires only the ALE1 program, not Alesta's other assets or employees, reducing integration risk. Closing is expected this quarter, subject to customary conditions.